Who are Gemcitabine combined with nab-paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gemcitabine plus Abraxane, Gemcitabine, Docetaxel, Gemcitabine combined with docetaxel, Gemcitabine + Nab-paclitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-combined-with-nab-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gemcitabine combined with nab-paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabine combined with nab-paclitaxel (Gemcitabine combined with nab-paclitaxel) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (nucleoside analog + taxane). Area: Oncology.

phase 3 Chemotherapy combination (nucleoside analog + taxane) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine combined with nab-paclitaxel (Gemcitabine combined with nab-paclitaxel) — Pancreatic Cancer Action Network. Gemcitabine and nab-paclitaxel work synergistically to disrupt cancer cell division by inhibiting DNA synthesis and microtubule dynamics, respectively.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gemcitabine combined with nab-paclitaxel TARGET	Gemcitabine combined with nab-paclitaxel	Pancreatic Cancer Action Network	phase 3	Chemotherapy combination (nucleoside analog + taxane)
Gemcitabine plus Abraxane	Gemcitabine plus Abraxane	ERYtech Pharma	phase 3	Chemotherapy combination (nucleoside analog + taxane)	DNA synthesis (gemcitabine); tubulin/microtubules (paclitaxel)
Gemcitabine, Docetaxel	Gemcitabine, Docetaxel	Central European Cooperative Oncology Group	phase 3	Chemotherapy combination (nucleoside analog + taxane)	DNA synthesis (gemcitabine); microtubule stabilization (docetaxel)
Gemcitabine combined with docetaxel	Gemcitabine combined with docetaxel	Hansoh BioMedical R&D Company	phase 3	Chemotherapy combination (nucleoside analog + taxane)	Ribonucleotide reductase (gemcitabine); β-tubulin/microtubules (docetaxel)
Gemcitabine + Nab-paclitaxel	Gemcitabine + Nab-paclitaxel	Verastem, Inc.	phase 3	Chemotherapy combination (nucleoside analog + taxane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (nucleoside analog + taxane) class)

Central European Cooperative Oncology Group · 1 drug in this class
ERYtech Pharma · 1 drug in this class
Hansoh BioMedical R&D Company · 1 drug in this class
Pancreatic Cancer Action Network · 1 drug in this class
Verastem, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine combined with nab-paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-combined-with-nab-paclitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab